Spots Global Cancer Trial Database for nras
Every month we try and update this database with for nras cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | NCT06026410 | Solid Tumors Wi... Non Small Cell ... Colorectal Canc... Pancreatic Duct... Clear Cell Rena... | KO-2806 Cabozantinib Adagrasib | 18 Years - | Kura Oncology, Inc. | |
| IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | NCT04109456 | Metastatic Mela... | IN10018 Cobimetinib Atezolizumab | 18 Years - | InxMed (Shanghai) Co., Ltd. | |
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | NCT03190941 | Pancreatic Canc... Gastric Cancer Gastrointestina... Colon Cancer Rectal Cancer | Cyclophosphamid... Fludarabine Anti-KRAS G12V ... Aldesleukin | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | NCT04249843 | Solid Tumor B-Raf Mutation-... | BGB-3245 | 18 Years - | MapKure, LLC | |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | NCT03597581 | Gastrointestina... Gastrointestina... Colorectal Canc... Colorectal Neop... Colorectal Carc... Gastric Cancer Gastric Neoplas... KRAS Mutation-R... CRC Colorectal Canc... | ompenaclid FOLFIRI Bevacizumab FOLFOX regimen | 18 Years - | Inspirna, Inc. | |
| Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | NCT03745326 | Gastrointestina... Pancreatic Canc... Gastric Cancer Colon Cancer Rectal Cancer | Cyclophosphamid... Fludarabine Aldesleukin anti-KRAS G12D ... | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers | NCT06194877 | Colorectal Canc... Pancreatic Duct... Advanced or Met... | BGB-3245 Panitumumab | 18 Years - | MapKure, LLC | |
| Study of HL-085 in NRAS Mutant Advanced Melanoma | NCT03973151 | Melanoma | HL-085 | 18 Years - 70 Years | Shanghai Kechow Pharma, Inc. | |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma | NCT06008106 | Melanoma | tunlametinib paclitaxel +car... | 18 Years - | Shanghai Kechow Pharma, Inc. | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | NCT02538627 | Colorectal Canc... Non-small Cell ... Squamous Cell C... | MM-151 MM-121 MM-141 trametinib | 18 Years - | Merrimack Pharmaceuticals | |
| A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | NCT01925274 | Metastatic Colo... | PF-05212384 irinotecan Cetuximab Irinotecan | 18 Years - | Pfizer | |
| Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | NCT02906059 | Metastatic Colo... | AZD1775 Irinotecan | 18 Years - | NYU Langone Health | |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | NCT03457896 | Metastatic Colo... | Trastuzumab Cetuximab Neratinib Guardant360 Dia... | 18 Years - | NSABP Foundation Inc | |
| Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma | NCT06008106 | Melanoma | tunlametinib paclitaxel +car... | 18 Years - | Shanghai Kechow Pharma, Inc. | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | NCT03637491 | Pancreatic Canc... | Avelumab Binimetinib Talazoparib | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
